2021³â ´ëÇѽÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ Ãß°èÇмú´ëȸ : 2021-11-20±³À°ÀÏÀÚ : 2021-11-20
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ´ë¾çAI¼¾ÅÍ AIȦ / ÄÁÆÛ·±½º·ë 1~3
±³À°ÁÖÁ¦ :
2021³â ´ëÇѽÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ Ãß°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇѽÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ(ÀÎ)
´ã´çÀÚ : ÃÖÀº¿µ
¿¬¶ôó : 02-2258-6030
À̸ÞÀÏ :
k-iscp@naver.com ±³À°Á¾·ù : ³»°ú, ½Å°æ¿Ü°úÀÇ»çÇÐ, ¿¹¹æÀÇÇÐ, ¾à¸®ÇÐ, ÀÇÇб³À°
Âü¼®¿¹»óÀοø : 50¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 8 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-20 08:50~09:00 °³È¸ ()
±³À°½Ã°£ 11-20 AIȦ 09:00~09:18 Combination therapy with low dose rivaroxaban in ACS ¹èÀåȯ(ÃæºÏ´ëº´¿ø ½ÉÀå³»°ú)
±³À°½Ã°£ 11-20 AIȦ 09:18~09:36 Role of PCSK9 inhibitors in ACS ÀÌ»óÇÐ(¿¬¼¼ÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 11-20 AIȦ 09:36~09:54 Colchicine use in ACS ¹ÚÈÆÁØ(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 11-20 AIȦ 09:54~10:12 Benefit of tight glycemic control during ACS À±Àç½Â(°¡Å縯ÀÇ´ë ³»ºÐºñ³»°ú)
Åä·Ð 11-20 AIȦ 10:12~10:30 ÇѽÂȯ(°¡ÃµÀÇ´ë ½ÉÀå³»°ú)
Åä·Ð 11-20 AIȦ 01:00~01:00 ±èµ¿¿î(ÃæºÏÀÇ´ë ½ÉÀå³»°ú)
Åä·Ð 11-20 AIȦ 01:00~01:00 ÀÌ¿Õ¼ö(Áß¾ÓÀÇ´ë ¼øȯ±â³»°ú)
Åä·Ð 11-20 AIȦ 01:00~01:00 ÀÓ¿µÈ¿(ÇѾçÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 11-20 ÄÁÆÛ·±½º·ë 1~3 09:10~09:30 ½ÉÇ÷°ü°è ¾à¹° ó¹æ½Ã ÁÖÀÇÇØ¾ß ÇÒ ¾à¹° »óÈ£ÀÛ¿ë ÀÌ¿Á»ó(¼¿ï´ëº´¿ø ¾àÁ¦ºÎ)
±³À°½Ã°£ 11-20 ÄÁÆÛ·±½º·ë 1~3 09:30~09:50 ½ÉÇ÷°ü°è ¾àÁ¦ Ä¡·á¿¡¼ ¾à¹° ³óµµ °Ë»ç(TDM)ÀÇ È¿¿ë¼º ÀÌÇØ¿µ(¼¿ïÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 11-20 ÄÁÆÛ·±½º·ë 1~3 09:50~10:10 ½ÉÇ÷°ü°è ¾à¹°ÀÇ °ú¿ë·® Åõ¿©½Ã ºñ»ó Ä¡·á ¿À±Ôö(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú)
Åä·Ð 11-20 ÄÁÆÛ·±½º·ë 1~3 10:10~10:30 ±èÀ¯°æ(¼¿ï¼º¸ðº´¿ø ¾àÁ¦ºÎ)
Åä·Ð 11-20 ÄÁÆÛ·±½º·ë 1~3 01:00~01:00 À̼±¾Æ(¾ÆÁִ뺴¿ø ¾àÁ¦ºÎ)
ÈÞ½Ä 11-20 10:30~10:50 ()
±³À°½Ã°£ 11-20 AIȦ 10:50~11:08 Pharmacologic treatment for isolated systolic hypertension ±è±¤ÀÏ(¼¿ïÀÇ´ë ³ëÀκ´³»°ú)
±³À°½Ã°£ 11-20 AIȦ 11:08~11:26 Pharmacologic treatment for morning hypertension ½ÅÁøÈ£(ÇѾçÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 11-20 AIȦ 11:26~11:44 Aldosterone antagonist and potassium sparing diuretics ¹Ú¼ºÇÏ(¿¬¼¼ÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 11-20 AIȦ 11:44~12:02 New drug therapy for resistant hypertension ±èÇзÉ(¼¿ïÀÇ´ë ¼øȯ±â³»°ú)
Åä·Ð 11-20 AIȦ 12:02~12:20 ±è¹ÌÁ¤(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú)
Åä·Ð 11-20 AIȦ 01:00~01:00 À¯½Â±â(À»ÁöÀÇ´ë ½ÉÀå³»°ú)
Åä·Ð 11-20 AIȦ 01:00~01:00 ÃÖö¿õ(°í·ÁÀÇ´ë ¼øȯ±â³»°ú)
Åä·Ð 11-20 AIȦ 01:00~01:00 ¹Ú»ó¹Î(À»ÁöÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 11-20 AIȦ 12:20~12:50 Optimal Treatment of Vasospastic Angina : Data from VA-Korea Study ¹é»óÈ«(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú)
½Ä»ç 11-20 12:50~13:20 ()
±³À°½Ã°£ 11-20 AIȦ 13:20~13:38 Pharmacologic Rhythm Control in Atrial Fibrillation Patients ±èÀ±±â(°í·ÁÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 11-20 AIȦ 13:38~13:56 Rate control agents Á¤·¡¿µ(ÀüºÏÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 11-20 AIȦ 13:56~14:14 Indication of Anticoagulation in patients with AF ±è¼ºÈ¯(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 11-20 AIȦ 14:14~14:32 Who will be the candidate for sinus conversion ¹ÚÁ¾¼º(µ¿¾ÆÀÇ´ë ¼øȯ±â³»°ú)
Åä·Ð 11-20 AIȦ 14:32~14:50 ÀÌ´ëÀÎ(ÃæºÏÀÇ´ë ½ÉÀå³»°ú)
Åä·Ð 11-20 AIȦ 01:00~01:00 ±èµ¿¹Î(´Ü±¹ÀÇ´ë ½ÉÀåÇ÷°ü³»°ú)
Åä·Ð 11-20 AIȦ 01:00~01:00 ±èµ¿Çõ(ÀÌÈÀÇ´ë ¼øȯ±â³»°ú)
Åä·Ð 11-20 AIȦ 01:00~01:00 ±èÀμö(¿¬¼¼ÀÇ´ë ½ÉÀå³»°ú)
ÈÞ½Ä 11-20 14:50~15:10 ()
±³À°½Ã°£ 11-20 AIȦ 15:10~15:28 Overview for major changes in pharmacotherapy ÃÖÁø¿À(¼º±Õ°üÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 11-20 AIȦ 15:28~15:46 What¡¯s new in HFrEF? ±èÀÎö(°è¸íÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 11-20 AIȦ 15:46~16:04 What¡¯s new in HFpEF? À±Á¾Âù(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 11-20 AIȦ 16:04~16:22 Targeted therapy for specific cardiomyopathy ±è¹Ì³ª(°í·ÁÀÇ´ë ¼øȯ±â³»°ú)
Åä·Ð 11-20 AIȦ 16:22~16:40 ÀÌÁÖÈñ(ÃæºÏÀÇ´ë ½ÉÀå³»°ú)
Åä·Ð 11-20 AIȦ 01:00~01:00 ±è¸í¾Æ(¼¿ïÀÇ´ë ¼øȯ±â³»°ú)
Åä·Ð 11-20 AIȦ 01:00~01:00 ±èÇý¹Ì(Áß¾ÓÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 11-20 16:40~17:30 ½Ã»ó ¹× Æóȸ ()